Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:55 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Gene-guided Warfarin for Anticoagulation Therapy
NCT04482842 · First Affiliated Hospital Xi'an Jiaotong University · NA · withdrawn · last registry update 2021-08-25 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “No participants enrolled” | – | Registry record, First Affiliated Hospital Xi'an Jiaotong University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against VKORC1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-08-25Phase 3 first posted: Instituto Mexicano del Seguro Social, Rivaroxaban 20 MG [Xarelto] + Aspirin 300mg (NCT05515120)
- 2022-07-26Results posted on the registry: Daiichi Sankyo, Edoxaban + Standard of Care (SOC) (NCT03395639)
- 2022-05-18Results posted on the registry: Bristol-Myers Squibb, Apixaban + Vitamin K Antagonist (VKA) (NCT02981472)
- 2022-03-04Also stopped (withdrawn): University of Louisville, a drug against VKORC1 (NCT03962400)
- 2022-01-26Phase 3 first posted: Saud Al Babtain Cardiac Center, Apixaban + Warfarin (NCT05208398)
- 2021-11-30Results posted on the registry: University of South Florida, Apixaban + Warfarin (NCT02283294)
- 2021-11-24Results posted on the registry: AtriCure, Inc., Anticoagulation Therapy (NCT02701062)
- 2021-08-19Also stopped (terminated): Rajaie Cardiovascular Medical and Research Center, Rivaroxaban + Warfarin (NCT03926156)
- 2021-07-22Results posted on the registry: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, rivaroxaban + Warfarin (NCT02376010)
- 2021-07-08Results posted on the registry: Universiti Sains Malaysia, Apixaban 5 MG Oral Tablet [ELIQUIS] + Warfarin Sodium (NCT02982590)
- 2021-03-25Also stopped (withdrawn): University of Texas Southwestern Medical Center, Warfarin (NCT03536208)
- 2021-03-16Results posted on the registry: Mayo Clinic, Apixaban + Warfarin (NCT03839355)
- 2021-03-16Also stopped (terminated): Mayo Clinic, Apixaban + Warfarin (NCT03839355)
- 2021-03-02Results posted on the registry: Qilu Hospital of Shandong University, Nadroparin calcium, warfarin (NCT04173429)
- 2021-01-29Phase 3 first posted: Kyushu University, Edoxaban + Warfarin Potassium (NCT04730037)
- 2021-01-27Phase 3 first posted: University of Birmingham, Warfarin + direct oral anticoagulants (NCT04727437)
- 2021-01-22Results posted on the registry: Sanford Health, Apixaban + Warfarin (NCT02889562)
- 2021-01-07Also stopped (terminated): Woman's Health University Hospital, Egypt, warfarin (NCT01569035)
- 2020-12-29Results posted on the registry: Christopher Granger, MD, apixaban + warfarin (NCT02942407)
- 2020-12-01Results posted on the registry: Imperial College London, Warfarin (NCT00180674)
- 2020-10-29Results posted on the registry: Abbott Medical Devices, Warfarin + acetylsalicylic acid (ASA) therapy (NCT02836652)
- 2020-10-19Results posted on the registry: Ohio State University, Atorvastatin + Anticoagulation Therapy (NCT02331095)
- 2020-10-19Also stopped (terminated): Ohio State University, Atorvastatin + Anticoagulation Therapy (NCT02331095)
- 2020-09-29Phase 3 first posted: Damascus University, Rivaroxaban + Warfarin (NCT04569279)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision